相关实验视频

Updated: Sep 17, 2025

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

在囊性纤维化中有效消灭Pseudomonas aeruginosa:多中心研究

Aynur Guliyeva¹, Cansu Yilmaz Yegit¹, Muruvvet Yanaz¹

¹Division of Pediatric Pulmonology, School of Medicine, Marmara University, Istanbul, Turkey.

Clinical pediatrics

|June 27, 2025

概括

在囊性纤维化 (CF) 患者中,修订后的Pseudomonas aeruginosa (PA) 根除方案显著提高了治疗成功率. 这种新的治疗方案优化了在CF护理中管理PA感染的结果.

科学领域:

医学研究医学研究
传染性疾病传染性疾病
肺部病理学肺部病理学

背景情况:

灭绝 Pseudomonas aeruginosa (PA) 对于治疗囊性纤维化 (CF) 是至关重要的.
该中心之前的根除成功率很低 (21.6%).
实施了修订后的协议,以提高PA根除效率.

研究的目的:

评估一种新的PA根除方案在CF患者中的有效性.
为了确定修订后的协议的成功率.
评估PA特征对治疗结果的影响.

主要方法:

包括首次检测到PA的CF患者.
非粘膜性PA病例接受了3周的口服西普罗夫洛克萨和1个月的吸入式托布拉米.
粘膜性PA或根除失败的病例接受了3周的西普罗夫洛克萨和3个月的交替吸入式托布拉米辛/胆固醇素;IV抗生素用于不良患者.

主要成果:

在109名CF患者中,达到72.5%的高根除率.
大多数 (60.6%) 接受了口服西普罗夫洛克萨和吸入式托布拉米.
延长的雾化治疗和静脉注射抗生素分别在23.8%和15.6%的患者中使用.

结论:

修订后的协议表明,在CF患者中,PA根除的成功率很高.
根据PA特征和患者状况量身定制治疗可以改善CF的管理.
优化治疗策略对于改善囊性纤维化护理结果至关重要.

关键词:

伪omonas aeruginosa 这种类型的病毒.囊性纤维化症是什么消灭的根除消灭的根除

更多相关视频

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

相关概念视频

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...